NY-ESO-1 Expression and Immunogenicity in Malignant and Benign Breast Tumors

Sugita, Yurika; Wada, Hisashi; Fujita, Shoichiro; Nakata, T.; Sato, Kimiyasu; Noguchi, Yuji; Jungbluth, Achim A.; Yamaguchi, M; Chen, Yao Tseng; Stockert, Elisabeth; Gnjatic, Sacha; Williamson, Barbara; Scanlan, Matthew J.; Ono, Toshiro; Sakita, Isao; Yasui, Masayoshi; Miyoshi, Yasuo; Tamaki, Yasuhiro; Matsuura, Nariaki; Noguchi, Shinzaburo; Old, Lloyd J.; Nakayama, Eiichi; Monden, Morito

doi:10.1158/0008-5472.can-03-3070

Cited by 89 publications

(90 citation statements)

References 25 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consequently, 75% of patients had tumours that expressed NY-ESO-1 at some stage during the course of the illness. 32 Acquisition of expression of CT Ag including NY-ESO-1 with advancing stage of disease has also been observed in multiple myeloma, 37 particularly in the setting of abnormal cytogenetics, 38 breast cancer, 5 non-small-cell lung cancer, 39,40 prostate cancer, 41 transitional cell carcinoma (TCC) of bladder, 42,43 gastric cancer, 44 colorectal cancer 45 and ovarian cancer. 46 In neuroblastoma, there was a notable level of expression of NY-ESO-1 in patients with later stage disease.…”

Section: Factors Affecting Ny-eso-1 Expression In Tumoursmentioning

confidence: 98%

“…Examples include SCC of the oesophagus, 27 one series of hepatocellular carcinoma, 47 carcinoma-in situ of the testis 22 and fibro-adenomas of the breast. 5 …”

Section: Factors Affecting Ny-eso-1 Expression In Tumoursmentioning

confidence: 99%

“…Ovary 2/8 (25%), 8 6/19 (32%), 44 42/107 (39%) 28 10/73 (14%), 46{ 62/143 (43%) 28 14 The highest reported levels were seen in synovial sarcomas (80-100%) 5 Soft tissue sarcoma 0/4 (0%), 2 19/68 (28%), 158 6/19 (32%), 14 13/36 (36%) 7 8/36 (22%), 7 7/19 (47%), 158 2/3 (66%), 4 or translation or to transfer of mRNA to the cytoplasm. 3 Other clues to the function of CT Ag might be inferred from observations of patterns of expression in normal tissues in the embryo and postnatal life and in cancer.…”

mentioning

confidence: 99%

“…3,4 Although NY-ESO-1 mRNA expression has been detected at low levels in some other normal tissues, it is unclear whether this is significant in the absence of detectable protein. 4,5 Other genes with similar names (NY-ESO-2, -3, -4, -5, -6, -7, -8) have no homology with NY-ESO-1. 2 The NY-ESO-1 gene is located on chromosome Xq28, 1 which carries a disproportionately high number of cancertestis (CT) Ag genes.…”

mentioning

confidence: 99%

“…Few of the X-linked CTAg have an ascribed function; for the few that do, the function is mainly related to RNA transcription 148 Chronic: 0/30 (0%) 148 Bladder transitional cell 20/62 (32%), 42 15/43 (35%), 43 7/16 (43%), 14 4/5 (80%) 8 2/14 (14%), 42 † 5/34 (15%), 43 2/9 (22%), 4 2/9 (22%) 4 † 17/34 (40%), 43 7/16 (43%) 14 Increased expression with higher grade disease 42 Breast 13/129, (10%), 149 13/98 (13%), 107 3/12 (25%), 14 10/33 (30%), 2 37/88 (42%), 5 12/27 (44%) 150 1/37 (3%), 5 † 2/14 (14%) 4 13/129 (10%), 149 3/12 (25%) 14 Low level expression in 68% of benign breast lesions, for example, fibro-adenoma 5 Cholangiocarcinoma (10%) 17 Colorectal 0/9 (0%), 14 0/16 (0%), 8 12/121 (10%), 45 2/98 (20%) 149 0/10 (0%) 4 † 0/9 (0%), 14 2/98 (2%) 149 Endometrial 7/130 (6%) 151 † Gastric 0/16 (0%), 8 8/102 (8%), 149 12/101 (12%) 44 8/102 (8%) 149 Head and neck SCC 3/45 (7%), 152 3/15 (20%) 14 0/10 (0%), 4 † 1/45 (2%) 152 ‡ 4/15 (27%) 14 Expression seen only in high-grade tumours 152 Hepatocellular carcinoma 0/21 (0%), 153 12/49 (24%), 154 17/62 (27%), 155 2/7 (29%), 8 31/73 (43%), …”

mentioning

confidence: 99%

See 4 more Smart Citations

Directions in the immune targeting of cancer: Lessons learned from the cancer‐testis Ag NY‐ESO‐1

et al. 2006

View full text Add to dashboard Cite

Summary Since the early 1990s, numerous cancer Ag have been defined and for a handful of these there is now some clinical experience, which has made it possible to assess their value as targets for cancer immunotherapy. The cancer-testis Ag have been particularly attractive because their expression is limited to cancer and virtually no nonmalignant cells apart from germ cells and trophoblast. Among these, NY-ESO-1 has been the focus of our attention. The exceptional immunogenicity of this Ag coupled with its widespread distribution among many cancer types make it a very good vaccine candidate, with the potential to be used in vaccines against many types of malignancies. This article reviews emerging knowledge about the biology of NY-ESO-1 and experience with the early clinical development of vaccines directed against NY-ESO-1. These early studies have yielded a wealth of information about the immunology of NY-ESO-1 and set the scene for future clinical strategies for immune targeting of cancer.Key words: cancer immunology, cancer-testis Ag, cancer vaccine, dendritic cell, ISCOMATRIX, NY-ESO-1. Biology of NY-ESO-1NY-ESO-1 was first discovered using 'SERological identification of antigens by recombinant EXpression cloning' (SEREX). This is a method used for identifying the antibody repertoire of cancer-bearing patients by screening their serum against an expression library that typically displays protein Ag derived from a cancer source such as an autologous tumour or a cell line. In this case, NY-ESO-1 was found by using serum from a patient with squamous cell carcinoma (SCC) of the oesophagus. 1,2 Expression of NY-ESO-1 protein has been shown in multiple cancer types (Table 1), as well as in spermatogonia, oogonia and placenta. 3,4 Although NY-ESO-1 mRNA expression has been detected at low levels in some other normal tissues, it is unclear whether this is significant in the absence of detectable protein. 4,5 Other genes with similar names (NY-ESO-2, -3, -4, -5, -6, -7, -8) have no homology with NY-ESO-1. 2 The NY-ESO-1 gene is located on chromosome Xq28, 1 which carries a disproportionately high number of cancertestis (CT) Ag genes. 6 Up to 10% of the genes on chromosome X are CT Ag genes. The expression of these genes seems to be related to the demethylation of the promoter regions because experimental demethylation leads to the upregulation of CT Ag expression. [7][8][9][10][11][12][13][14][15][16][17][18] The NY-ESO-1 gene encodes a protein of 180 amino acids with M r 18 kDa, 2 which is expressed primarily in the cytoplasm although nuclear expression can be seen in some spermatogonia. 4 A homologue of NY-ESO-1, termed LAGE-1, was identified using representational difference analysis. 14 LAGE-1 and NY-ESO-1 are 84-89% homologous at the protein level. 14 Alternative splicing of LAGE-1 mRNA leads to the expression of two major transcripts encoding proteins of 210 and 180 amino acids, respectively. LAGE-1 is expressed in a wide variety of cancers (Table 1), usually, but not always, in conjunction with NY-ESO-1 or ...

show abstract

Section: Factors Affecting Ny-eso-1 Expression In Tumoursmentioning

confidence: 98%

“…Examples include SCC of the oesophagus, 27 one series of hepatocellular carcinoma, 47 carcinoma-in situ of the testis 22 and fibro-adenomas of the breast. 5 …”

Section: Factors Affecting Ny-eso-1 Expression In Tumoursmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Directions in the immune targeting of cancer: Lessons learned from the cancer‐testis Ag NY‐ESO‐1

et al. 2006

View full text Add to dashboard Cite

show abstract

Serum NY‐ESO‐1 and p53 antibodies as useful tumor markers in gastric cancer

Kawada,

Saito,

Kurokawa

et al. 2023

Annals of Gastroent Surgery

Self Cite

View full text Add to dashboard Cite

PurposeThe NY‐ESO‐1 antigen is highly immunogenic and often spontaneously induces an immune response in patients with cancer. We conducted a large‐scale multicenter cohort study to investigate the utility of serum NY‐ESO‐1 and p53 antibodies as predictive markers for the postoperative recurrence of gastric cancer. Here, we examined the usefulness of pre‐treatment NY‐ESO‐1 and p53 antibodies as tumor markers for the diagnosis of gastric cancer in combination with carcinoembryonic antigen (CEA) and carbohydrate antigen 19‐9 (CA19‐9).MethodsA total of 1031 patients with cT3‐4 gastric cancer were enrolled in the study. NY‐ESO‐1 and p53 antibodies were assessed prior to treatment. The positivity of NY‐ESO‐1 and p53 antibodies, CEA, and CA19‐9 was evaluated before treatment.ResultsSerum NY‐ESO‐1 and p53 antibodies were positive in 12.6% and 18.1% of the patients, respectively. Positive NY‐ESO‐1 antibody response was correlated with male gender, higher cStage, and upper tumor location. However, a positive p53 antibody response was not associated with tumor factors. The combination of NY‐ESO‐1 or p53 antibody response with CEA and CA19‐9, or the 4‐factors, was positive in 45.1%, 49.6%, and 53.8% of patients, respectively. Moreover, the 4‐factor combination was able to detect >60% of cStage III‐IV diseases, which was 14% higher than that with the combination of CEA and CA19‐9.ConclusionThe combination of NY‐ESO‐1 and p53 antibody responses to CEA and CA19‐9 increases the diagnostic accuracy of gastric cancer. Serum NY‐ESO‐1 and p53 antibodies may be useful tumor markers for gastric cancer.

show abstract

Optimization of norovirus virus‐like particle production in Pichia pastoris using a real‐time near‐infrared bioprocess monitor

Parker

Maloy

Tomé-Amat

et al. 2016

Biotechnology Progress

View full text Add to dashboard Cite

The production of norovirus virus-like particles (NoV VLPs) displaying NY-ESO-1 cancer testis antigen in Pichia pastoris BG11 Mut(+) has been enhanced through feed-strategy optimization using a near-infrared bioprocess monitor (RTBio(®) Bioprocess Monitor, ASL Analytical, Inc.), capable of monitoring and controlling the concentrations of glycerol and methanol in real-time. The production of NoV VLPs displaying NY-ESO-1 in P. pastoris has potential as a novel cancer vaccine platform. Optimization of the growth conditions resulted in an almost two-fold increase in the expression levels in the fermentation supernatant of P. pastoris as compared to the starting conditions. We investigated the effect of methanol concentration, batch phase time, and batch to induction transition on NoV VLP-NY-ESO-1 production. The optimized process included a glycerol transition phase during the first 2 h of induction and a methanol concentration set point of 4 g L(-1) during induction. Utilizing the bioprocess monitor to control the glycerol and methanol concentrations during induction resulted in a maximum NoV VP1-NY-ESO-1 yield of 0.85 g L(-1) . © 2016 American Institute of Chemical Engineers Biotechnol. Prog., 32:518-526, 2016.

show abstract

NY-ESO-1 Expression and Immunogenicity in Malignant and Benign Breast Tumors

Cited by 89 publications

References 25 publications

Directions in the immune targeting of cancer: Lessons learned from the cancer‐testis Ag NY‐ESO‐1

Directions in the immune targeting of cancer: Lessons learned from the cancer‐testis Ag NY‐ESO‐1

Serum NY‐ESO‐1 and p53 antibodies as useful tumor markers in gastric cancer

Optimization of norovirus virus‐like particle production in Pichia pastoris using a real‐time near‐infrared bioprocess monitor

Contact Info

Product

Resources

About